<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cardioversion for specific arrhythmias</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cardioversion for specific arrhythmias</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cardioversion for specific arrhythmias</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard L Page, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Electrical cardioversion and defibrillation are commonly used procedures in the management of patients with cardiac arrhythmias. </p><p class="bulletIndent1"><span class="glyph">●</span>Cardioversion is the delivery of energy to the chest that is synchronized to the QRS complex and is used for converting rhythms in patients who are hemodynamically stable and tend to have monomorphic QRS complexes. As an example, elective outpatient cardioversions are routinely performed on patients with persistent atrial fibrillation (AF) to restore sinus rhythm  (<a class="graphic graphic_movie graphicRef131981" href="/z/d/graphic/131981.html" rel="external">movie 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Defibrillation is asynchronous delivery of a shock randomly during the cardiac cycle and is typically used during a cardiac arrest caused by ventricular fibrillation.</p><p></p><p>This topic will review the clinical settings in which electrical cardioversion and defibrillation are used, along with a brief discussion of the complications that can occur independent of the arrhythmia that is being treated. The basic principles and technique of electrical cardioversion and defibrillation, the specific indications for external cardioversion and defibrillation, and the use of the automated external defibrillator are presented separately. (See  <a class="medical medical_review" href="/z/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1042.html" rel="external">"Automated external defibrillators"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">EXTERNAL CARDIOVERSION/DEFIBRILLATION</span></p><p class="headingAnchor" id="H5724431"><span class="h2">Preparation and personnel</span><span class="headingEndMark"> — </span>Nonemergency electrical cardioversion should ideally be performed in a controlled environment with monitoring capabilities and the nearby availability of emergency equipment should complications arise. The following are considered part of the routine preparation and monitoring involved in electrical cardioversion:</p><p class="bulletIndent1"><span class="glyph">●</span>Standard cardiorespiratory monitoring, including blood pressure, pulse, oxygen saturation, end-tidal CO<sub>2</sub> monitoring, and cardiac telemetry.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous access for administration of sedation and for management of any rhythm-related complications (ie, ventricular fibrillation, sinus bradycardia, etc).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Available supplemental oxygen, suction device, and intubation equipment for management of respiratory complications (though supplemental oxygen should be removed prior to delivery of the electrical shock) (see <a class="local">'Supplemental oxygen'</a> below).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Available code cart with medications used in advanced cardiac life support in the event of life-threatening arrhythmias (see  <a class="medical medical_review" href="/z/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is considerable activation of thoracic skeletal muscles during a transthoracic shock that causes patients and their arms to move during a shock. For this reason, and because these patients are anticoagulated, padding or cushioning should be placed between the patient's extremities and any hard bed railings to avoid injury during cardioversion.</p><p></p><p>While many cardiologists are trained in the administration of moderate sedation, sedation may also be administered by an anesthesiologist who can immediately assist in the management of respiratory complications should any develop. An advantage of having an anesthesiologist routinely administer sedation for elective cardioversions is that at many hospitals, the use of ultra-short acting sedatives such as <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> is restricted to anesthesiologists. The tradeoff for such involvement is often added costs and scheduling complexity. (See  <a class="medical medical_review" href="/z/d/html/264.html" rel="external">"Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications", section on 'Anticipating and mitigating Complications'</a>.)</p><p>Elective cardioversions for AF and atrial flutter are usually performed by cardiologists but can also be safely performed autonomously by a midlevel provider. With appropriate training and a protocol that includes a guideline-directed procedural checklist  (<a class="graphic graphic_table graphicRef121196" href="/z/d/graphic/121196.html" rel="external">table 1</a>), physician supervision, and sedation administered by an anesthesiologist, an advanced practice nurse can safely perform cardioversions autonomously with outcomes and patient satisfaction similar to those for cardioversions performed by a physician [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H9896272"><span class="h2">Supplemental oxygen</span><span class="headingEndMark"> — </span>Supplemental oxygen is a fire hazard in the event of electrical arcing during external cardioversion or defibrillation. Because of this, supplemental oxygen flow should be stopped, or the oxygen delivery device (eg, nasal cannula, face mask, etc) removed from the patient, prior to the delivery of an external shock. Oxygen flow can be restarted after the shock has been delivered.</p><p class="headingAnchor" id="H1172679957"><span class="h2">Paddle/pad placement</span><span class="headingEndMark"> — </span>For electrical cardioversion of atrial tachyarrhythmias, particularly AF, an anterior-posterior pad position is preferred to anterior-lateral placement  (<a class="graphic graphic_figure graphicRef103268" href="/z/d/graphic/103268.html" rel="external">figure 1</a>) based on evidence from several randomized trials that have shown higher success rates and lower energy requirements for successful cardioversion with the anterior-posterior configuration [<a href="#rid2">2,3</a>]. The historical rationale for the superiority of the anterior-posterior position is a more favorable shock vector through the atria as well as reduced transthoracic impedance. Moreover, there is some evidence that applying external force to self-adhesive electrodes may decrease transthoracic impedance further [<a href="#rid4">4</a>]. However, pad placement may not significantly affect outcomes of cardioversion with contemporary defibrillator devices that employ impedance compensated biphasic waveforms [<a href="#rid5">5</a>]. For urgent cardioversion/defibrillation of unstable rhythms, an anterior-lateral pad configuration may be preferred for ease of application, and device manufacturer recommendations should be followed in all cases. (See  <a class="medical medical_review" href="/z/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation", section on 'Electrodes'</a>.)</p><p class="headingAnchor" id="H2562597"><span class="h2">Energy selection</span><span class="headingEndMark"> — </span>The amount of energy selected for initial attempts of cardioversion or defibrillation has been controversial. The energy selected should be sufficient to accomplish prompt cardioversion or defibrillation because repeated failures expose the heart to damage from prolonged ischemia and multiple shocks. On the other hand, excessive energy should be avoided, since myocardial damage from high-energy shocks has been demonstrated in experimental studies, although the frequency with which this occurs in humans is not known [<a href="#rid6">6,7</a>].</p><p>Early defibrillators delivered energy in a monophasic waveform, meaning that electrons flowed in a single direction. The newer defibrillators deliver a biphasic waveform, meaning that during the shock, polarity and electron flow reverse. In addition to reversing polarity, biphasic defibrillators also deliver a more consistent magnitude of current  (<a class="graphic graphic_figure graphicRef51842" href="/z/d/graphic/51842.html" rel="external">figure 2</a>). In general, biphasic defibrillators successfully terminate arrhythmias at lower energies than monophasic defibrillators. The relative efficacy of biphasic and monophasic defibrillators has been compared in a number of settings and is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation", section on 'Monophasic versus biphasic waveforms'</a>.)</p><p>While nearly all available external defibrillators now use a biphasic waveform, it is still important to fully understand the type of waveform that is delivered when using an external defibrillator. For example, the Zoll brand of external defibrillators uses a truncated waveform that results in the delivery of more current to the heart compared to defibrillators made by other manufacturers that use a standard biphasic waveform, when set to deliver the same amount of energy in joules. Unlike most defibrillators that deliver a maximum energy of 360 joules, the Zoll defibrillators have a maximum energy setting of 200 joules but deliver similar current to the heart with comparable defibrillation efficacy. The energy selection recommendations in this topic are in joules and are for defibrillators that use a standard biphasic waveform. Lower energies can be used with defibrillators that use a truncated biphasic waveform.</p><p>In 2010, the American Heart Association issued guidelines for cardiopulmonary resuscitation and emergency cardiovascular care that discussed detailed starting energy levels for treatment of various types of arrhythmias [<a href="#rid8">8</a>]. In the 2014 AHA/ACC/HRS guidelines on the management of AF, no specific energy levels for cardioversion or defibrillation are discussed, but some broad concepts are presented. We agree with the suggested initial energy selection for specific arrhythmias as addressed in the society guidelines, with the following suggested initial energy requirements for monophasic and biphasic waveforms [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>When available, a biphasic defibrillator is preferred due to greater efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For AF, 120 to 200 joules  (<a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For atrial flutter, 50 to 100 joules.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For ventricular tachycardia with a pulse, 100 joules.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For ventricular fibrillation or pulseless ventricular tachycardia, 200 to 360 joules  (<a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To increase the likelihood of initial shock success and reduce the duration of sedation, a higher initial energy may be considered, particularly in obese patients or in patients known to be difficult to cardiovert.</p><p></p><p>When an external defibrillator is being prepared to deliver a rescue shock in the event that an implantable defibrillator fails to convert a patient during defibrillation threshold testing, the energy should be set to the maximum output and in the asynchronous mode.</p><p>Cardioversion with higher energy levels may be effective when prior cardioversion attempts using a maximal energy of 360 joules have failed to restore sinus rhythm. In one study, 55 patients who did not have sinus rhythm restored after at least two attempts of external cardioversion with 360 joules underwent cardioversion with 720 joules, which was performed by using two external cardioverters, each connected to its own pair of patches [<a href="#rid9">9</a>]. Sinus rhythm was restored in 84 percent of these patients with no major complications, hemodynamic compromise, or strokes occurring after the procedure.</p><p>As another option besides high-energy cardioversion, pretreatment with an antiarrhythmic drug can facilitate cardioversion at lower energy levels. Pretreatment with <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> prior to electrical cardioversion has been shown to significantly improve the rate of successful cardioversion to sinus rhythm and was also associated with the use of significantly lower energy levels to achieve cardioversion [<a href="#rid10">10</a>]. <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, and <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a> have also been shown to increase the likelihood of successful cardioversion or lower the energy threshold required for cardioversion [<a href="#rid11">11</a>]. When an antiarrhythmic drug is chosen, however, the potential side effects must be carefully considered. (See  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a> and  <a class="medical medical_review" href="/z/d/html/925.html" rel="external">"Clinical uses of sotalol"</a>.)</p><p class="headingAnchor" id="H2901695961"><span class="h2">Synchronization</span><span class="headingEndMark"> — </span>When delivering energy to the chest to defibrillate a patient who is experiencing ventricular fibrillation, the energy is delivered promptly as soon as the shock button is pressed on the defibrillator.</p><p>In contrast, when cardioverting a patient who is hemodynamically stable, it is critical that the energy is not delivered during the electrically vulnerable period during the QT interval as this could inadvertently induce ventricular fibrillation. Synchronized cardioversion prevents induction of ventricular fibrillation by delivering the energy synchronous with the QRS complex.</p><p class="bulletIndent1"><span class="glyph">●</span>To perform synchronous cardioversion, the external defibrillator must be set to synchronous mode by pressing the "synchronize" button. This should result in markers displayed on what the device has determined are the QRS complexes during the arrhythmia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is important to ensure that the markers are accurately placed on the QRS complexes before shocking the patient. When the QRS voltage is small, the markers may be inaccurate. At times, it may be necessary to select a different ECG lead that shows a prominent QRS complex to improve synchronization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the defibrillator is set to synchronous mode, the shock button must be depressed and held until a QRS is detected and the shock is delivered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the first shock fails to convert the arrhythmia and a second shock is being planned, it is critical to resynchronize the defibrillator. Most external defibrillators will default back to asynchronous mode after a shock is delivered. Failure to resynchronize the defibrillator can lead to induction of ventricular fibrillation in a patient intended to undergo cardioversion.</p><p></p><p class="headingAnchor" id="H1682749"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>External cardioversion and defibrillation have been used in the treatment of a variety of arrhythmias, with variable results depending on the chronicity of the arrhythmia, triggers for the arrhythmia, and the patient’s overall clinical condition. For example, electrical cardioversion success rates approach 100 percent in patients with atrial flutter or AF of short duration and no structural heart disease, while the success rates are much lower in patients with chronic AF and concomitant mitral valve disease. The term "failed cardioversion" can indicate failure to restore sinus rhythm at all, or an immediate recurrence of the arrhythmia. It is important to differentiate these two failure mechanisms because different approaches can be used to address each type of failure.</p><p>While antiarrhythmic medications can sometimes result in restoration of sinus rhythm without electrical cardioversion, they are primarily used in an effort to maintain sinus rhythm following successful electrical cardioversion. However, many antiarrhythmic drugs can alter the defibrillation threshold, ie, the minimal amount of energy necessary for reversion of an arrhythmia  (<a class="graphic graphic_table graphicRef81781" href="/z/d/graphic/81781.html" rel="external">table 2</a>). <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, and <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> may cause a significant rise in defibrillation thresholds [<a href="#rid12">12-15</a>]. (See  <a class="medical medical_review" href="/z/d/html/926.html" rel="external">"Amiodarone: Clinical uses"</a> and  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Atrial fibrillation</span><span class="headingEndMark"> — </span>AF is the most frequent arrhythmia treated with electrical cardioversion  (<a class="graphic graphic_movie graphicRef131981" href="/z/d/graphic/131981.html" rel="external">movie 1</a>). Cardioversion is part of the overall treatment approach to AF, which also includes rate control and anticoagulation.</p><p>To reduce the risk of thromboembolism following cardioversion, therapeutic anticoagulation is generally recommended for at least three to four weeks before and after cardioversion. Alternatively, the presence of existing intracardiac thrombus should be excluded using transesophageal echocardiography prior to cardioversion if therapeutic anticoagulation has not been achieved for an adequate duration. However, a negative TEE does not preclude the need for anticoagulation at the time of the cardioversion or afterwards. Detailed discussions regarding the decision to perform cardioversion versus rate control, as well as the optimal approach to anticoagulation, are provided elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion"</a> and  <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a> and  <a class="medical medical_review" href="/z/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/908.html" rel="external">"Role of echocardiography in atrial fibrillation", section on 'Transesophageal echocardiography'</a>.)</p><p>The energy requirement for successful cardioversion of AF varies according to the type of electrical waveform and chronicity of AF  (<a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">algorithm 1</a>) [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation", section on 'Energy selection for cardioversion and defibrillation'</a>.)</p><p>Most currently available defibrillators deliver biphasic waveforms. When biphasic waveforms are used, the efficacy is higher [<a href="#rid16">16,17</a>]. In a study of 912 patients with AF or atrial flutter, restoration of sinus rhythm was higher with the use of biphasic waveforms (94 versus 84 percent for monophasic waveforms) and the cumulative energy was lower (199 J versus 554 J) [<a href="#rid16">16</a>]. The use of biphasic waveforms may be of particular benefit in patients who fail to revert with the use of monophasic waveforms [<a href="#rid18">18</a>].</p><p>Although it had been hoped that cardioversion to and maintenance of sinus rhythm would improve the prognosis of and reduce embolic risk in patients with AF, this concept was not confirmed in the two largest randomized trials comparing rate control plus anticoagulation versus rhythm control for AF (the AFFIRM and RACE trials) [<a href="#rid19">19,20</a>]. Both studies showed a trend toward a lower incidence of the primary endpoint with rate control and anticoagulation (hazard ratio 0.87 for mortality in AFFIRM and 0.73 for a composite endpoint in RACE). In addition, embolization occurred with equal frequency regardless of whether a rhythm control or a rate control strategy was adopted. In both groups, embolization primarily occurred after <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> had been stopped or when the INR was subtherapeutic. (See  <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Atrial flutter</span><span class="headingEndMark"> — </span>Electrical cardioversion is highly successful in the treatment of typical (type I) atrial flutter, which arises from a single reentrant circuit in the right atrium  (<a class="graphic graphic_waveform graphicRef75931" href="/z/d/graphic/75931.html" rel="external">waveform 1</a> and <a class="graphic graphic_figure graphicRef52904" href="/z/d/graphic/52904.html" rel="external">figure 3</a>). The energy requirement for successful cardioversion of typical (type I) atrial flutter is usually lower than that required for AF  (<a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">algorithm 1</a>) [<a href="#rid8">8</a>]. Many patients with type I atrial flutter can be cardioverted with 50 to 100 joules or less [<a href="#rid21">21-24</a>]. In a review including 985 cardioversions in 840 patients with atrial flutter, the median energy level for successful cardioversion was 50 joules with a biphasic defibrillator [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/1069.html" rel="external">"Restoration of sinus rhythm in atrial flutter"</a> and  <a class="medical medical_review" href="/z/d/html/1061.html" rel="external">"Electrocardiographic and electrophysiologic features of atrial flutter"</a> and  <a class="medical medical_review" href="/z/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation", section on 'Energy selection for cardioversion and defibrillation'</a>.)</p><p>In contrast to typical (type I) atrial flutter, atypical (type II) atrial flutter may result from reentrant circuits in various locations and tends to require higher energy levels for cardioversion, but in most cases sinus rhythm can be successfully restored. While starting at 50 to 100 joules may be effective for cardioversion of atypical (type II) atrial flutter, particularly with biphasic defibrillators, this approach has the potential adverse effect of requiring additional shocks [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/1061.html" rel="external">"Electrocardiographic and electrophysiologic features of atrial flutter"</a>.)</p><p>The role of anticoagulation during and after cardioversion is similar to that with AF and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1066.html" rel="external">"Embolic risk and the role of anticoagulation in atrial flutter"</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Supraventricular tachycardia</span><span class="headingEndMark"> — </span>The most common mechanisms for supraventricular tachycardia are atrioventricular (AV) nodal reentry, AV reentrant tachycardia, and atrial tachycardia. These arrhythmias often terminate with vagal maneuvers or intravenous antiarrhythmic therapy with <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> or <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> when they are AV nodal dependent; as such, electrical cardioversion is usually not required. However, if these arrhythmias persist and electrical cardioversion is attempted, cardioversion is usually successful but may require relatively high energy levels, probably due to the deep location of the reentrant pathway. If sinus rhythm is not restored following an initial 50 to 100 joule shock, subsequent shocks should be at higher energy levels  (<a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Ventricular tachycardia</span><span class="headingEndMark"> — </span>Electrical cardioversion is usually successful in the acute treatment of ventricular tachycardia (VT), which typically arises from a reentrant circuit in the ventricle. If a distinct QRS and T wave are identified, allowing the delivery of energy to be synchronized to the QRS complex, monomorphic VT can often be terminated with a low-energy shock. Despite the potential for terminating VT with very low-energy shocks, one must consider the seriousness of the arrhythmia and the desire to avoid repeated shocks. As a result, the initial synchronized shock in these circumstances is recommended to be 100 joules  (<a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">algorithm 1</a>) [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/1040.html" rel="external">"Sustained monomorphic ventricular tachycardia in patients with structural heart disease: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation", section on 'Energy selection for cardioversion and defibrillation'</a>.)</p><p>In contrast, synchronized cardioversion may be impossible or hazardous if the VT is rapid and distinct QRS complexes are not identified, if the QRS complexes are wide and bizarre, or if the VT is polymorphic. In these settings, there is a potential for delivery of a discharge on the T wave, possibly provoking ventricular fibrillation. Under these circumstances, nonsynchronized defibrillation should be performed starting with 200 joules for a biphasic device. (See  <a class="medical medical_review" href="/z/d/html/916.html" rel="external">"Catecholaminergic polymorphic ventricular tachycardia"</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Ventricular fibrillation</span><span class="headingEndMark"> — </span>The only definitive treatment for ventricular fibrillation (VF) is defibrillation. When defibrillation is performed promptly, the success rate for terminating ventricular fibrillation can be as high as 95 percent [<a href="#rid25">25-28</a>]. However, the success rate falls substantially as the duration of ventricular fibrillation increases, probably due to myocardial ischemia, acidosis, and other metabolic changes. These cellular changes are associated with an electrophysiologic deterioration of ventricular fibrillation, leading to an increase in fibrillation cycle length and prolonged diastolic duration between fibrillation action potentials [<a href="#rid29">29</a>].</p><p>For these reasons, defibrillation as soon as possible has been considered to be the standard of care for VF  (<a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">algorithm 2</a>). Some studies suggest that when VF has been present for longer than four to five minutes, outcomes are better if cardiopulmonary resuscitation is performed prior to defibrillation [<a href="#rid30">30,31</a>]. The recommended starting energy to effectively defibrillate VF is 200 joules with biphasic waveforms  (<a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">algorithm 1</a>) [<a href="#rid8">8</a>]. There is no reported benefit to using more than 360 joules, and there may be harm since high-energy shocks may be associated with myocardial damage and the risk for developing new arrhythmias. (See  <a class="medical medical_review" href="/z/d/html/1028.html" rel="external">"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest", section on 'Defibrillation'</a> and  <a class="medical medical_review" href="/z/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults", section on 'Pulseless ventricular tachycardia and ventricular fibrillation'</a> and  <a class="medical medical_review" href="/z/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation", section on 'Energy selection for cardioversion and defibrillation'</a> and <a class="local">'Complications'</a> below.)</p><p class="headingAnchor" id="H3424080"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H18"><span class="h3">Cardioversion during pregnancy</span><span class="headingEndMark"> — </span>Cardioversion can be performed during pregnancy without affecting the rhythm of the fetus [<a href="#rid32">32,33</a>]. It is recommended, however, that the fetal heart rate be monitored during the procedure using standard fetal monitoring techniques. (See  <a class="medical medical_review" href="/z/d/html/409.html" rel="external">"Nonstress test and contraction stress test"</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Cardioversion in patients with permanent pacemakers/ICDs</span><span class="headingEndMark"> — </span>Several precautions are necessary when attempting external electrical cardioversion or defibrillation in a patient with a permanent pacemaker or an implantable cardioverter-defibrillator (ICD). Defibrillation in these patients can damage the pulse generator, the lead system, or the myocardial tissue, resulting in device dysfunction [<a href="#rid34">34</a>]. The electrode paddle (or patch) should be at least 12 cm from the pulse generator and an anteroposterior paddle position is recommended [<a href="#rid35">35,36</a>]. Elective cardioversion should be initiated with the lowest indicated energy (which will vary depending on the arrhythmia) in order to avoid damage to the device circuitry and the electrode-myocardial interface. After cardioversion, the pacemaker should be interrogated and evaluated to ensure normal pacemaker function. When these precautions have been used, cardioversion with either monophasic or biphasic shocks is safe and effective in patients with an implantable device [<a href="#rid37">37</a>].</p><p>Alternatively, in patients with an ICD, internal cardioversion can be attempted by an electrophysiologist using the device programmer to deliver the shock. (See <a class="local">'Internal cardioversion/defibrillation'</a> below.)</p><p class="headingAnchor" id="H2561692"><span class="h3">Cardioversion in patients with digitalis toxicity</span><span class="headingEndMark"> — </span>Patients with digitalis overdose or intoxication can present with almost any type of arrhythmia, including tachyarrhythmias and bradyarrhythmias. In particular, ventricular arrhythmias (including VF) are more likely to occur in patients who have digitalis toxicity, especially if the patient is also hypokalemic. There is a relative contraindication to cardioversion in the setting of digitalis toxicity since digitalis sensitizes the heart to the electrical stimulus and, hence, cardioversion could trigger additional arrhythmias, most importantly ventricular fibrillation.</p><p class="bulletIndent1"><span class="glyph">●</span>Supraventricular arrhythmias – Cardioversion should be deferred until digitalis levels have returned to a normal range and clinical toxicity has resolved. If urgent restoration of sinus rhythm is necessary for a hemodynamically unstable supraventricular arrhythmia, the lowest energy that is likely to be successful should be used. In addition, rapid atrial pacing may be successful for certain arrhythmias (eg, atrial flutter) and is probably the safest method. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Electrical cardioversion'</a> and  <a class="medical medical_review" href="/z/d/html/1069.html" rel="external">"Restoration of sinus rhythm in atrial flutter", section on 'Atrial overdrive pacing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular arrhythmias – If cardioversion must be performed for a life-threatening ventricular arrhythmia, prophylactic <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> (1 mg/kg up to a maximum dose of 100 mg IV push) should be given and the lowest indicated energy levels used.</p><p></p><p>When time permits, hypokalemia should be corrected prior to cardioversion. (See  <a class="medical medical_review" href="/z/d/html/319.html" rel="external">"Digitalis (cardiac glycoside) poisoning"</a>.)</p><p class="headingAnchor" id="H2560757"><span class="h2">Complications</span><span class="headingEndMark"> — </span>While electrical cardioversion and defibrillation are generally well tolerated, complications may occur. Most complications are self-limiting (eg, changes in the electrocardiogram, hypotension related to sedation and/or vasodilation) or relatively benign (eg, skin irritation). However, providers should be aware of potential life-threatening complications such as postcardioversion arrhythmias and the possibility of thromboembolism.</p><p class="headingAnchor" id="H2560837"><span class="h3">ST segment and T wave changes</span><span class="headingEndMark"> — </span>Electrocardiographic (ECG) changes can occur immediately after cardioversion, usually consisting of ST segment and T wave changes [<a href="#rid38">38-42</a>]. ECG changes, including ST segment elevation, are nonspecific findings and should not be used as the sole criteria for identifying an acute ischemic event as the cause for the ventricular tachyarrhythmia [<a href="#rid42">42</a>].</p><p>In one study of 56 patients with ventricular arrhythmias treated with monophasic shocks, ST segment and T wave changes were common immediately after cardioversion but usually resolved within five minutes [<a href="#rid38">38</a>]. The ECG changes included ST segment elevation in 15 percent, ST segment depression in 35 percent, or an increase in T wave amplitude.</p><p>Transient ST elevation has also been reported in a series of patients undergoing cardioversion with monophasic waveforms for atrial arrhythmias [<a href="#rid39">39</a>]. These changes were noted primarily in the precordial leads, and normalized within 1.5 minutes. The occurrence of ST segment elevation was associated with a lower conversion rate and lower rate of long-term maintenance of sinus rhythm.</p><p>The pathogenesis of ST elevation is uncertain, since elevations in cardiac enzymes (ie, CK-MB and troponin) are uncommon and, when they occur, are usually minimal [<a href="#rid43">43-45</a>]. However, both the incidence and the extent of ST segment changes appear to be lower with the use of biphasic waveforms [<a href="#rid46">46,47</a>].</p><p class="headingAnchor" id="H2560844"><span class="h3">Arrhythmia and conduction abnormalities</span><span class="headingEndMark"> — </span>Arrhythmias are frequently observed after cardioversion [<a href="#rid38">38,48-51</a>]. In many cases these arrhythmias are benign (eg, sinus tachycardia, nonsustained ventricular tachycardia [VT]), but in other cases the arrhythmias can be clinically and/or hemodynamically significant (eg, ventricular fibrillation [VF], sustained VT).</p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular arrhythmias – Runs of nonsustained ventricular tachycardia (VT) are seen in up to five percent of patients, and can occur in patients with or without structural heart disease [<a href="#rid38">38</a>]. On the other hand, a sustained ventricular arrhythmia generally occurs only in patients with clinically documented VT or long-lasting VF [<a href="#rid38">38,49</a>]. Cardioversion can also induce VF, usually but not always after the administration of an asynchronous shock [<a href="#rid49">49</a>]. The occurrence of ventricular arrhythmias does not appear to be related to the number of shocks and cannot be prevented by antiarrhythmic therapy. Conversely, antiarrhythmic drugs may contribute to the development of new arrhythmias [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atrial arrhythmias – Atrial arrhythmias can also occur following cardioversion. Approximately 30 percent of patients have a supraventricular tachycardia, primarily sinus tachycardia. However, AV nodal reentrant tachycardia and atrial flutter have been observed following cardioversion attempts for chronic AF [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bradyarrhythmias and conduction abnormalities – Bradyarrhythmias following electrical cardioversion are relatively rare. In a retrospective multicenter cohort study of 6906 electrical cardioversions in 2868 patients with AF and less than 48 hours of symptoms, bradyarrhythmias were identified following 63 cardioversions (0.9 percent) in 54 patients [<a href="#rid53">53</a>]. Pre-procedure use of <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, beta blocker, or antiarrhythmic drug did not impact the development of bradyarrhythmias post-cardioversion. Nevertheless, it is reasonable to anticipate clinically significant bradycardia in patients undergoing cardioversion who have been in AF for over a year, have very slow ventricular rates during AF, or in whom <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> loading was recently administered.</p><p></p><p>A transient left bundle branch block is occasionally seen after cardioversion, but high-degree atrioventricular block is more common. In one study of 75 patients who underwent 112 shocks, sinus bradycardia occurred in 18 patients and high-degree AV block in 11 [<a href="#rid48">48</a>]. Temporary pacing was necessary in 10 patients. The likelihood of requiring either external or transvenous cardiac pacing immediately after a cardioversion is much lower in clinical practice than this study suggests. The incidence appears to be less than 1 percent. Patients receiving antiarrhythmic drugs are more prone to develop bradycardia and asystole and an external pacemaker should be readily available in such patients [<a href="#rid48">48,49</a>]. (See  <a class="medical medical_review" href="/z/d/html/1005.html" rel="external">"Temporary cardiac pacing"</a>.)</p><p class="headingAnchor" id="H2560851"><span class="h3">Thromboembolism</span><span class="headingEndMark"> — </span>Cardioversion may be associated with pulmonary or systemic thromboembolism. Thromboembolism after the return of synchronous atrial contraction can occur because of dislodgement of left atrial thrombi present at the time of cardioversion or a thrombus that forms after cardioversion due to transient post conversion left atrial mechanical dysfunction. This complication is more likely to occur in patients with AF who have not been anticoagulated prior to cardioversion. Patients with a previous embolism do not have an increased risk of embolization if anticoagulation of adequate intensity and length are administered [<a href="#rid54">54</a>]. The estimated incidence of thromboembolism varies, but in a large nonrandomized series that included 437 patients, thromboembolism occurred in 5.3 percent of patients who were not anticoagulated compared with 0.8 percent of those who were receiving anticoagulation [<a href="#rid55">55</a>]. For patients with AF of at least 48 hours duration, the current recommendation is to anticoagulate patients for several weeks prior to and following cardioversion. (See  <a class="medical medical_review" href="/z/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a>.)</p><p class="headingAnchor" id="H2560858"><span class="h3">Myocardial necrosis</span><span class="headingEndMark"> — </span>Minimal myocardial necrosis, particularly of the epicardium, may occur as a result of high-energy shocks. This is typically asymptomatic and is manifested by small rises in serum CK-MB and troponin levels. In contrast, substantial elevations of either CK-MB or troponin following electrical cardioversion, or the development of chest pain suggestive of angina, suggests the presence of myocardial injury from causes unrelated to the procedure. As such, we do not routinely monitor cardiac enzymes following electrical cardioversion in asymptomatic patients.</p><p>Although the cause is unknown, it has been suggested that myocardial necrosis may be due to the sustained depolarization of a critical mass of myocardial cells [<a href="#rid40">40</a>]. The risk of myocardial necrosis appears related to the amount of energy delivered with each shock rather than to the number of shocks, although many repeated shocks may lead to myocardial damage and scarring.</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 30 patients who underwent cardioversion, an increase in serum CK-MB was seen in only two patients, despite substantial release of CK from skeletal muscle [<a href="#rid56">56</a>]. Furthermore, the small release of CK-MB in this report cannot be considered diagnostic for myocardial damage since the total CK from skeletal muscle includes approximately 1 percent CK-MB [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The desire for improved specificity in the diagnosis of myocardial injury has led to measurement of the serum troponin levels. Among 38 patients undergoing elective cardioversion, only three patients had minimal elevations of troponin I (0.8 to 1.5 mcg/L), suggesting subtle myocardial injury [<a href="#rid44">44</a>]. Two other studies, however, reported no elevations in troponin T following cardioversion [<a href="#rid45">45,58</a>].</p><p></p><p class="headingAnchor" id="H2560865"><span class="h3">Myocardial dysfunction</span><span class="headingEndMark"> — </span>Global left ventricular dysfunction due to myocardial stunning may be seen in patients with cardiac arrest who have undergone successful cardiopulmonary resuscitation. This is related in part to defibrillation, but is also a result of the arrhythmia itself and due to the absence of cardiac output and coronary blood flow during the period of arrest with resultant ischemia. Myocardial dysfunction due to stunning may reverse within the first 24 to 48 hours after cardiac arrest. It is routine to image the heart and evaluate ventricular function shortly after a patient suffers a cardiac arrest to determine if there is evidence of structural heart disease. This evaluation should not be delayed. However, it is important to recognize that ventricular dysfunction may be transient and that imaging should be repeated within a few days if ventricular dysfunction is present immediately after the arrest [<a href="#rid59">59</a>].</p><p>In animals, the severity of postresuscitation myocardial dysfunction is related, in part, to the energy used for defibrillation [<a href="#rid60">60</a>]. Further support for this observation comes from another animal study comparing biphasic and monophasic waveforms for reversion of ventricular fibrillation [<a href="#rid61">61</a>]. Although lower-energy biphasic waveforms were as effective as higher-energy monophasic waveforms for restoration of sinus rhythm, there was less myocardial dysfunction after defibrillation with the use of biphasic waveforms.</p><p>The process of electrical cardioversion may transiently injure or "stun" the atria as well [<a href="#rid62">62,63</a>].</p><p class="headingAnchor" id="H2560872"><span class="h3">Pulmonary edema</span><span class="headingEndMark"> — </span>Pulmonary edema is a rare complication of cardioversion, which is probably due to transient left atrial standstill or left ventricular dysfunction. It is unrelated to the amount of energy used. Pulmonary edema may be more common in patients with AF associated with valvular heart disease or left ventricular dysfunction. In this setting, the return of atrial systole after cardioversion can result in a significant elevation in left atrial pressure and pulmonary edema [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H2560879"><span class="h3">Transient hypotension</span><span class="headingEndMark"> — </span>Transient hypotension can occur for several hours after cardioversion. Most patients require no therapy; if necessary, the fall in blood pressure usually responds to fluid replacement [<a href="#rid65">65</a>]. Although the mechanism is not certain, the hypotension may be related to vasodilation or the use of sedation during the procedure.</p><p class="headingAnchor" id="H2560886"><span class="h3">Cutaneous burns</span><span class="headingEndMark"> — </span>Following cardioversion or defibrillation, skin burns occur in 20 to 25 percent of patients and are more likely with improper technique and placement of electrodes [<a href="#rid66">66</a>]. The risk of burns is less with the use of biphasic waveforms and the use of gel-based pads [<a href="#rid67">67</a>]. The use of steroid cream, <a class="drug drug_general" data-topicid="9890" href="/z/d/drug information/9890.html" rel="external">silver sulfadiazine</a> cream, or topical <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> reduces the pain and inflammation [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H20"><span class="h1">INTERNAL CARDIOVERSION/DEFIBRILLATION</span></p><p class="headingAnchor" id="H3424163"><span class="h2">Technique and efficacy</span><span class="headingEndMark"> — </span>Internal or intracardiac cardioversion is an effective technique for patients in whom external cardioversion has failed to restore sinus rhythm. However, the need for internal cardioversion has been greatly diminished due to the efficacy of biphasic waveform defibrillators and the availability of <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> in restoring sinus rhythm. In addition, given the invasive nature of the procedure, specialized training is required to perform internal cardioversion. An ACC/AHA task force on clinical competency has published recommendations for technical and cognitive skills needed to perform internal direct current cardioversion  (<a class="graphic graphic_table graphicRef57223 graphicRef65048" href="/z/d/graphic/57223.html" rel="external">table 3A-B</a>) [<a href="#rid70">70</a>].</p><p>Internal cardioversion can be performed in various ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Using a preexisting ICD to deliver a clinician-directed shock.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using epicardial wires placed during surgery or internal paddles applied directly to the epicardium in a patient with a sternotomy [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two defibrillation electrodes are placed in the right atrium and coronary sinus or in the right atrium and left pulmonary artery, respectively, and then intracardiac shocks are delivered by an external defibrillator.</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Internal cardioversion complications</span><span class="headingEndMark"> — </span>Although internal cardioversion is an effective approach for restoring sinus rhythms in patients with AF refractory to pharmacologic or external electrical cardioversion, one study reported that complications occurred in 19 percent of patients, including low cardiac output from ventricular stunning, pericardial effusion, and a brief period of ventricular asystole requiring ventricular pacing [<a href="#rid72">72</a>]. Another report of 25 patients found that 36 percent developed transient bradycardia, related to sinus and atrioventricular nodal depression, requiring temporary ventricular pacing [<a href="#rid73">73</a>]. Shocks of up to 20 joules did not affect the function of permanent pacemakers.</p><p class="headingAnchor" id="H25"><span class="h2">Implantable cardioverter-defibrillators</span><span class="headingEndMark"> — </span>ICDs are in widespread use in patients with a history of sustained ventricular tachycardia or ventricular fibrillation and also for primary prevention in selected patients. In patients with an ICD, internal cardioversion can be attempted by a cardiologist using the device programmer to deliver the shock. The advantage of using the ICD is that it avoids the risk of a skin irritation from an external shock and the small chance of damage to the ICD system from the shock. The disadvantage of using the ICD is that it consumes some of the battery in the device and does not always work for cardioversion of atrial arrhythmias. Indications for and efficacy of ICDs are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/921.html" rel="external">"Implantable cardioverter-defibrillators: Overview of indications, components, and functions"</a> and  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p class="headingAnchor" id="H2684076369"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">"Society guideline links: Ventricular arrhythmias"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16443.html" rel="external">"Patient education: Heart failure and atrial fibrillation (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3435.html" rel="external">"Patient education: Cardioversion (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3442.html" rel="external">"Patient education: Implantable cardioverter-defibrillators (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H289870"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Electrical cardioversion and defibrillation are commonly performed procedures in the management of patients with cardiac arrhythmias. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardioversion is the delivery of energy to the chest that is synchronized to the QRS complex; it is used for converting rhythms with monomorphic QRS complexes in patients who are hemodynamically stable  (<a class="graphic graphic_movie graphicRef131981" href="/z/d/graphic/131981.html" rel="external">movie 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Defibrillation is asynchronous delivery of a shock randomly during the cardiac cycle and is typically used during a cardiac arrest caused by ventricular fibrillation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Energy selection</strong> – When available, a biphasic defibrillator is preferred due to greater efficacy. Nearly all available external defibrillators now use a biphasic waveform. However, it is still important to fully understand the type of waveform that is delivered when using an external defibrillator. The energy selection recommendations in this topic are in joules and are for defibrillators that use a standard biphasic waveform. Lower energies can be used with defibrillators that use a truncated biphasic waveform. (See <a class="local">'Energy selection'</a> above.)</p><p></p><p class="bulletIndent1">Once an arrhythmia has been identified, the most important factor in the likelihood of a successful cardioversion or defibrillation is the choice of the initial energy level to be delivered to the patient. To increase the likelihood of initial shock success and reduce the duration of sedation, a higher initial energy may be considered. The following are suggested initial energy requirements for monophasic and biphasic waveforms (see  <a class="medical medical_review" href="/z/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation", section on 'Energy selection for cardioversion and defibrillation'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For AF, 120 to 200 joules  (<a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">algorithm 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>For atrial flutter, 50 to 100 joules</p><p class="bulletIndent2"><span class="glyph">•</span>For ventricular tachycardia with a pulse, 100 joules</p><p class="bulletIndent2"><span class="glyph">•</span>For ventricular fibrillation or pulseless ventricular tachycardia, 200 to 360 joules  (<a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">algorithm 2</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – External cardioversion and defibrillation have been used in the treatment of a variety of arrhythmias, with variable results depending on the chronicity of the arrhythmia, triggers for the arrhythmia, and the patient’s overall clinical condition. The term "failed cardioversion" can indicate failure to restore sinus rhythm at all, or an immediate recurrence of the arrhythmia. It is important to differentiate these two failure mechanisms because different approaches can be used to address each type of failure. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atrial fibrillation or atrial flutter</strong> – Electrical cardioversion success rates approach 100 percent in patients with atrial flutter or atrial fibrillation (AF) of short duration and no structural heart disease, while the success rates are much lower in patients with chronic AF and concomitant mitral valve disease. (See <a class="local">'Atrial fibrillation'</a> above and <a class="local">'Atrial flutter'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ventricular tachycardia</strong> – Electrical cardioversion is usually successful in the acute treatment of ventricular tachycardia. If a distinct QRS and T wave are identified, synchronized cardioversion can be attempted. In contrast, synchronized cardioversion may be impossible or hazardous if distinct QRS complexes are not identified. As such, under these circumstances, asynchronous defibrillation should be used. (See <a class="local">'Ventricular tachycardia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ventricular fibrillation</strong> – Defibrillation is the only definitive treatment for ventricular fibrillation (VF), with high success rates when performed promptly. However, the success rate falls substantially as the duration of ventricular fibrillation increases, probably due to myocardial ischemia, acidosis, and other metabolic changes. For these reasons, defibrillation as soon as possible has been considered to be the standard of care for VF  (<a class="graphic graphic_algorithm graphicRef129983" href="/z/d/graphic/129983.html" rel="external">algorithm 2</a>). (See <a class="local">'Ventricular fibrillation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – While electrical cardioversion and defibrillation are generally well tolerated, complications may occur. Most complications are self-limited (eg, changes in the electrocardiogram, hypotension related to sedation and/or vasodilation) or relatively benign (eg, skin irritation). However, providers should be aware of potential life-threatening complications such as post-cardioversion arrhythmias and thromboembolism. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Internal cardioversion</strong> – Internal or intracardiac cardioversion is an effective technique for patients in whom external cardioversion has failed to restore sinus rhythm. The need for internal cardioversion has been greatly diminished due to the efficacy of biphasic waveform defibrillators in restoring sinus rhythm. Given the invasive nature of the procedure, specialized training is required to perform internal cardioversion. (See <a class="local">'Internal cardioversion/defibrillation'</a> above.)</p><p></p><p class="headingAnchor" id="H4058641990"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ramsey Wehbe, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Strzelczyk TA, Kaplan RM, Medler M, Knight BP. Outcomes Associated With Electrical Cardioversion for Atrial Fibrillation When Performed Autonomously by an Advanced Practice Provider. JACC Clin Electrophysiol 2017; 3:1447.</a></li><li><a class="nounderline abstract_t">Kirchhof P, Eckardt L, Loh P, et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 2002; 360:1275.</a></li><li><a class="nounderline abstract_t">Botto GL, Politi A, Bonini W, et al. External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements. Heart 1999; 82:726.</a></li><li><a class="nounderline abstract_t">Ramirez FD, Fiset SL, Cleland MJ, et al. Effect of Applying Force to Self-Adhesive Electrodes on Transthoracic Impedance: Implications for Electrical Cardioversion. Pacing Clin Electrophysiol 2016; 39:1141.</a></li><li><a class="nounderline abstract_t">Walsh SJ, McCarty D, McClelland AJ, et al. Impedance compensated biphasic waveforms for transthoracic cardioversion of atrial fibrillation: a multi-centre comparison of antero-apical and antero-posterior pad positions. Eur Heart J 2005; 26:1298.</a></li><li><a class="nounderline abstract_t">Dahl CF, Ewy GA, Warner ED, Thomas ED. Myocardial necrosis from direct current countershock. Effect of paddle electrode size and time interval between discharges. Circulation 1974; 50:956.</a></li><li><a class="nounderline abstract_t">Warner ED, Dahl C, Ewy GA. Myocardial injury from transthoracic defibrillator countershock. Arch Pathol 1975; 99:55.</a></li><li><a class="nounderline abstract_t">Link MS, Atkins DL, Passman RS, et al. Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S706.</a></li><li><a class="nounderline abstract_t">Saliba W, Juratli N, Chung MK, et al. Higher energy synchronized external direct current cardioversion for refractory atrial fibrillation. J Am Coll Cardiol 1999; 34:2031.</a></li><li><a class="nounderline abstract_t">Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340:1849.</a></li><li><a class="nounderline abstract_t">Sung RJ. Facilitating electrical cardioversion of persistant atrial fibrillation by antiarrhythmic drugs: update on clinical trial results. Card Electrophysiol Rev 2003; 7:300.</a></li><li><a class="nounderline abstract_t">Babbs CF, Yim GK, Whistler SJ, et al. Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs. Am Heart J 1979; 98:345.</a></li><li><a class="nounderline abstract_t">Troup PJ, Chapman PD, Olinger GN, Kleinman LH. The implanted defibrillator: relation of defibrillating lead configuration and clinical variables to defibrillation threshold. J Am Coll Cardiol 1985; 6:1315.</a></li><li><a class="nounderline abstract_t">Tacker WA Jr, Niebauer MJ, Babbs CF, et al. The effect of newer antiarrhythmic drugs on defibrillation threshold. Crit Care Med 1980; 8:177.</a></li><li><a class="nounderline abstract_t">Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol 1989; 63:112.</a></li><li><a class="nounderline abstract_t">Gurevitz OT, Ammash NM, Malouf JF, et al. Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter. Am Heart J 2005; 149:316.</a></li><li><a class="nounderline abstract_t">Page RL, Kerber RE, Russell JK, et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol 2002; 39:1956.</a></li><li><a class="nounderline abstract_t">Khaykin Y, Newman D, Kowalewski M, et al. Biphasic versus monophasic cardioversion in shock-resistant atrial fibrillation:. J Cardiovasc Electrophysiol 2003; 14:868.</a></li><li><a class="nounderline abstract_t">Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.</a></li><li><a class="nounderline abstract_t">Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.</a></li><li><a class="nounderline abstract_t">Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.</a></li><li><a class="nounderline abstract_t">Niebauer MJ, Brewer JE, Chung MK, Tchou PJ. Comparison of the rectilinear biphasic waveform with the monophasic damped sine waveform for external cardioversion of atrial fibrillation and flutter. Am J Cardiol 2004; 93:1495.</a></li><li><a class="nounderline abstract_t">Gallagher MM, Guo XH, Poloniecki JD, et al. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol 2001; 38:1498.</a></li><li><a class="nounderline abstract_t">Mortensen K, Risius T, Schwemer TF, et al. Biphasic versus monophasic shock for external cardioversion of atrial flutter: a prospective, randomized trial. Cardiology 2008; 111:57.</a></li><li><a class="nounderline abstract_t">Faddy SC, Powell J, Craig JC. Biphasic and monophasic shocks for transthoracic defibrillation: a meta analysis of randomised controlled trials. Resuscitation 2003; 58:9.</a></li><li><a class="nounderline abstract_t">Morrison LJ, Dorian P, Long J, et al. Out-of-hospital cardiac arrest rectilinear biphasic to monophasic damped sine defibrillation waveforms with advanced life support intervention trial (ORBIT). Resuscitation 2005; 66:149.</a></li><li><a class="nounderline abstract_t">Martens PR, Russell JK, Wolcke B, et al. Optimal Response to Cardiac Arrest study: defibrillation waveform effects. Resuscitation 2001; 49:233.</a></li><li><a class="nounderline abstract_t">Stothert JC, Hatcher TS, Gupton CL, et al. Rectilinear biphasic waveform defibrillation of out-of-hospital cardiac arrest. Prehosp Emerg Care 2004; 8:388.</a></li><li><a class="nounderline abstract_t">Tovar OH, Jones JL. Electrophysiological deterioration during long-duration ventricular fibrillation. Circulation 2000; 102:2886.</a></li><li><a class="nounderline abstract_t">Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA 1999; 281:1182.</a></li><li><a class="nounderline abstract_t">Wik L, Hansen TB, Fylling F, et al. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial. JAMA 2003; 289:1389.</a></li><li><a class="nounderline abstract_t">VOGEL JH, PRYOR R, BLOUNT SG Jr. DIRECT-CURRENT DEFIBRILLATION DURING PREGNANCY. JAMA 1965; 193:970.</a></li><li><a class="nounderline abstract_t">Schroeder JS, Harrison DC. Repeated cardioversion during pregnancy. Treatment of refractory paroxysmal atrial tachycardia during 3 successive pregnancies. Am J Cardiol 1971; 27:445.</a></li><li><a class="nounderline abstract_t">Waller C, Callies F, Langenfeld H. Adverse effects of direct current cardioversion on cardiac pacemakers and electrodes Is external cardioversion contraindicated in patients with permanent pacing systems? Europace 2004; 6:165.</a></li><li><a class="nounderline abstract_t">Gould L, Patel S, Gomes GI, Chokshi AB. Pacemaker failure following external defibrillation. Pacing Clin Electrophysiol 1981; 4:575.</a></li><li><a class="nounderline abstract_t">Levine PA, Barold SS, Fletcher RD, Talbot P. Adverse acute and chronic effects of electrical defibrillation and cardioversion on implanted unipolar cardiac pacing systems. J Am Coll Cardiol 1983; 1:1413.</a></li><li><a class="nounderline abstract_t">Manegold JC, Israel CW, Ehrlich JR, et al. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: a randomized comparison of monophasic and biphasic shock energy application. Eur Heart J 2007; 28:1731.</a></li><li><a class="nounderline abstract_t">Eysmann SB, Marchlinski FE, Buxton AE, Josephson ME. Electrocardiographic changes after cardioversion of ventricular arrhythmias. Circulation 1986; 73:73.</a></li><li><a class="nounderline abstract_t">Van Gelder IC, Crijns HJ, Van der Laarse A, et al. Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter. Am Heart J 1991; 121:51.</a></li><li><a class="nounderline abstract_t">Chun PK, Davia JE, Donohue DJ. ST-segment elevation with elective DC cardioversion. Circulation 1981; 63:220.</a></li><li><a class="nounderline abstract_t">Zelinger AB, Falk RH, Hood WB Jr. Electrical-induced sustained myocardial depolarization as a possible cause for transient ST elevation post-DC elective cardioversion. Am Heart J 1982; 103:1073.</a></li><li><a class="nounderline abstract_t">Kok LC, Mitchell MA, Haines DE, et al. Transient ST elevation after transthoracic cardioversion in patients with hemodynamically unstable ventricular tachyarrhythmia. Am J Cardiol 2000; 85:878.</a></li><li><a class="nounderline abstract_t">Reiffel JA, Gambino SR, McCarthy DM, Leahey EB Jr. Direct current cardioversion. Effect on creatine kinase, lactic dehydrogenase and myocardial isoenzymes. JAMA 1978; 239:122.</a></li><li><a class="nounderline abstract_t">Allan JJ, Feld RD, Russell AA, et al. Cardiac troponin I levels are normal or minimally elevated after transthoracic cardioversion. J Am Coll Cardiol 1997; 30:1052.</a></li><li><a class="nounderline abstract_t">Neumayr G, Hagn C, Gänzer H, et al. Plasma levels of troponin T after electrical cardioversion of atrial fibrillation and flutter. Am J Cardiol 1997; 80:1367.</a></li><li><a class="nounderline abstract_t">Reddy RK, Gleva MJ, Gliner BE, et al. Biphasic transthoracic defibrillation causes fewer ECG ST-segment changes after shock. Ann Emerg Med 1997; 30:127.</a></li><li><a class="nounderline abstract_t">Ambler JJ, Deakin CD. A randomized controlled trial of efficacy and ST change following use of the Welch-Allyn MRL PIC biphasic waveform versus damped sine monophasic waveform for external DC cardioversion. Resuscitation 2006; 71:146.</a></li><li><a class="nounderline abstract_t">Waldecker B, Brugada P, Zehender M, et al. Dysrhythmias after direct-current cardioversion. Am J Cardiol 1986; 57:120.</a></li><li><a class="nounderline abstract_t">DeSilva RA, Graboys TB, Podrid PJ, Lown B. Cardioversion and defibrillation. Am Heart J 1980; 100:881.</a></li><li><a class="nounderline abstract_t">LEMBERG L, CASTELLANOS A Jr, SWENSON J, GOSSELIN A. ARRHYTHMIAS RELATED TO CARDIOVERSION. Circulation 1964; 30:163.</a></li><li><a class="nounderline abstract_t">PELESKA B. CARDIAC ARRHYTHMIAS FOLLOWING CONDENSER DISCHARGES AND THEIR DEPENDENCE UPON STRENGTH OF CURRENT AND PHASE OF CARDIAC CYCLE. Circ Res 1963; 13:21.</a></li><li><a class="nounderline abstract_t">Cohen TJ, Scheinman MM, Pullen BT, et al. Emergency intracardiac defibrillation for refractory ventricular fibrillation during routine electrophysiologic study. J Am Coll Cardiol 1991; 18:1280.</a></li><li><a class="nounderline abstract_t">Grönberg T, Nuotio I, Nikkinen M, et al. Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study. Europace 2013; 15:1432.</a></li><li><a class="nounderline abstract_t">Elhendy A, Gentile F, Khandheria BK, et al. Safety of electrical cardioversion in patients with previous embolic events. Mayo Clin Proc 2001; 76:364.</a></li><li><a class="nounderline abstract_t">Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969; 23:208.</a></li><li><a class="nounderline abstract_t">Ehsani A, Ewy GA, Sobel BE. Effects of electrical countershock on serum creatine phosphokinase (CPK) isoenzyme activity. Am J Cardiol 1976; 37:12.</a></li><li><a class="nounderline abstract_t">Lindberg K, Lundin A, Nordlander R, et al. Detection of acute myocardial infarction by a new, sensitive and rapid method for determination of creatine kinase B-subunit activity. Eur Heart J 1980; 1:327.</a></li><li><a class="nounderline abstract_t">Goktekin O, Melek M, Gorenek B, et al. Cardiac troponin T and cardiac enzymes after external transthoracic cardioversion of ventricular arrhythmias in patients with coronary artery disease. Chest 2002; 122:2050.</a></li><li><a class="nounderline abstract_t">Kern KB, Hilwig RW, Rhee KH, Berg RA. Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning. J Am Coll Cardiol 1996; 28:232.</a></li><li><a class="nounderline abstract_t">Xie J, Weil MH, Sun S, et al. High-energy defibrillation increases the severity of postresuscitation myocardial dysfunction. Circulation 1997; 96:683.</a></li><li><a class="nounderline abstract_t">Sun S, Klouche K, Tang W, Weil MH. The effects of biphasic and conventional monophasic defibrillation on postresuscitation myocardial function. J Am Coll Cardiol 2001; 37:1753.</a></li><li><a class="nounderline abstract_t">Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22:1359.</a></li><li><a class="nounderline abstract_t">Omran H, Jung W, Rabahieh R, et al. Left atrial chamber and appendage function after internal atrial defibrillation: a prospective and serial transesophageal echocardiographic study. J Am Coll Cardiol 1997; 29:131.</a></li><li><a class="nounderline abstract_t">Gowda RM, Misra D, Khan IA, Schweitzer P. Acute pulmonary edema after cardioversion of cardiac arrhythmias. Int J Cardiol 2003; 92:271.</a></li><li><a class="nounderline abstract_t">Resnekov L. High-energy electrical current and myocardial damage. Med Instrum 1978; 12:24.</a></li><li><a class="nounderline abstract_t">Ambler JJ, Sado DM, Zideman DA, Deakin CD. The incidence and severity of cutaneous burns following external DC cardioversion. Resuscitation 2004; 61:281.</a></li><li><a class="nounderline abstract_t">Ambler JJ, Deakin CD. A randomised controlled trial of the effect of biphasic or monophasic waveform on the incidence and severity of cutaneous burns following external direct current cardioversion. Resuscitation 2006; 71:293.</a></li><li><a class="nounderline abstract_t">Ambler JJ, Zideman DA, Deakin CD. The effect of prophylactic topical steroid cream on the incidence and severity of cutaneous burns following external DC cardioversion. Resuscitation 2005; 65:179.</a></li><li><a class="nounderline abstract_t">Ambler JJ, Zideman DA, Deakin CD. The effect of topical non-steroidal anti-inflammatory cream on the incidence and severity of cutaneous burns following external DC cardioversion. Resuscitation 2005; 65:173.</a></li><li><a class="nounderline abstract_t">Tracy CM, Akhtar M, DiMarco JP, et al. American College of Cardiology/American Heart Association Clinical Competence Statement on invasive electrophysiology studies, catheter ablation, and cardioversion: A report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence. Circulation 2000; 102:2309.</a></li><li><a class="nounderline abstract_t">Liebold A, Wahba A, Birnbaum DE. Low-energy cardioversion with epicardial wire electrodes: new treatment of atrial fibrillation after open heart surgery. Circulation 1998; 98:883.</a></li><li><a class="nounderline abstract_t">Mansourati J, Larlet JM, Salaun G, et al. Safety of high energy internal cardioversion for atrial fibrillation. Pacing Clin Electrophysiol 1997; 20:1919.</a></li><li><a class="nounderline abstract_t">Prakash A, Saksena S, Mathew P, Krol RB. Internal atrial defibrillation: effect on sinus and atrioventricular nodal function and implanted cardiac pacemakers. Pacing Clin Electrophysiol 1997; 20:2434.</a></li></ol></div><div id="topicVersionRevision">Topic 983 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759676" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Outcomes Associated With Electrical Cardioversion for Atrial Fibrillation When Performed Autonomously by an Advanced Practice Provider.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12414201" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573502" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27550777" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effect of Applying Force to Self-Adhesive Electrodes on Transthoracic Impedance: Implications for Electrical Cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824079" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impedance compensated biphasic waveforms for transthoracic cardioversion of atrial fibrillation: a multi-centre comparison of antero-apical and antero-posterior pad positions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4430099" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Myocardial necrosis from direct current countershock. Effect of paddle electrode size and time interval between discharges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1111497" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Myocardial injury from transthoracic defibrillator countershock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956222" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588220" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Higher energy synchronized external direct current cardioversion for refractory atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369847" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14739733" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Facilitating electrical cardioversion of persistant atrial fibrillation by antiarrhythmic drugs: update on clinical trial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/157692" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4067110" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The implanted defibrillator: relation of defibrillating lead configuration and clinical variables to defibrillation threshold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7363635" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The effect of newer antiarrhythmic drugs on defibrillation threshold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2491771" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effects of flecainide on the atrial defibrillation threshold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846271" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12084594" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12890051" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Biphasic versus monophasic cardioversion in shock-resistant atrial fibrillation:.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12466506" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A comparison of rate control and rhythm control in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12466507" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908781" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194019" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparison of the rectilinear biphasic waveform with the monophasic damped sine waveform for external cardioversion of atrial fibrillation and flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11691530" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18239394" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Biphasic versus monophasic shock for external cardioversion of atrial flutter: a prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867304" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Biphasic and monophasic shocks for transthoracic defibrillation: a meta analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15992986" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Out-of-hospital cardiac arrest rectilinear biphasic to monophasic damped sine defibrillation waveforms with advanced life support intervention trial (ORBIT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719116" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Optimal Response to Cardiac Arrest study: defibrillation waveform effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625999" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rectilinear biphasic waveform defibrillation of out-of-hospital cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11104749" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Electrophysiological deterioration during long-duration ventricular fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199427" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12636461" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14341154" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : DIRECT-CURRENT DEFIBRILLATION DURING PREGNANCY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5572585" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Repeated cardioversion during pregnancy. Treatment of refractory paroxysmal atrial tachycardia during 3 successive pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15018877" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Adverse effects of direct current cardioversion on cardiac pacemakers and electrodes Is external cardioversion contraindicated in patients with permanent pacing systems?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6169045" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pacemaker failure following external defibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6853897" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adverse acute and chronic effects of electrical defibrillation and cardioversion on implanted unipolar cardiac pacing systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17569681" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: a randomized comparison of monophasic and biphasic shock energy application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3940671" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Electrocardiographic changes after cardioversion of ventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985377" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7438397" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : ST-segment elevation with elective DC cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7081022" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Electrical-induced sustained myocardial depolarization as a possible cause for transient ST elevation post-DC elective cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10758932" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Transient ST elevation after transthoracic cardioversion in patients with hemodynamically unstable ventricular tachyarrhythmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/579371" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Direct current cardioversion. Effect on creatine kinase, lactic dehydrogenase and myocardial isoenzymes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9316538" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cardiac troponin I levels are normal or minimally elevated after transthoracic cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9388119" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Plasma levels of troponin T after electrical cardioversion of atrial fibrillation and flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250633" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Biphasic transthoracic defibrillation causes fewer ECG ST-segment changes after shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16987583" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A randomized controlled trial of efficacy and ST change following use of the Welch-Allyn MRL PIC biphasic waveform versus damped sine monophasic waveform for external DC cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510522" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dysrhythmias after direct-current cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7004155" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cardioversion and defibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14205541" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : ARRHYTHMIAS RELATED TO CARDIOVERSION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14042825" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : CARDIAC ARRHYTHMIAS FOLLOWING CONDENSER DISCHARGES AND THEIR DEPENDENCE UPON STRENGTH OF CURRENT AND PHASE OF CARDIAC CYCLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1918705" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Emergency intracardiac defibrillation for refractory ventricular fibrillation during routine electrophysiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687124" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11322351" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Safety of electrical cardioversion in patients with previous embolic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4180019" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1244729" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effects of electrical countershock on serum creatine phosphokinase (CPK) isoenzyme activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7274245" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Detection of acute myocardial infarction by a new, sensitive and rapid method for determination of creatine kinase B-subunit activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12475846" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cardiac troponin T and cardiac enzymes after external transthoracic cardioversion of ventricular arrhythmias in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752819" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9244243" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : High-energy defibrillation increases the severity of postresuscitation myocardial dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11345396" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The effects of biphasic and conventional monophasic defibrillation on postresuscitation myocardial function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8227792" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996305" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Left atrial chamber and appendage function after internal atrial defibrillation: a prospective and serial transesophageal echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14659864" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Acute pulmonary edema after cardioversion of cardiac arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/634185" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : High-energy electrical current and myocardial damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172706" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The incidence and severity of cutaneous burns following external DC cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996194" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A randomised controlled trial of the effect of biphasic or monophasic waveform on the incidence and severity of cutaneous burns following external direct current cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15866398" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The effect of prophylactic topical steroid cream on the incidence and severity of cutaneous burns following external DC cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15866397" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The effect of topical non-steroidal anti-inflammatory cream on the incidence and severity of cutaneous burns following external DC cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11056109" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : American College of Cardiology/American Heart Association Clinical Competence Statement on invasive electrophysiology studies, catheter ablation, and cardioversion: A report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738643" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Low-energy cardioversion with epicardial wire electrodes: new treatment of atrial fibrillation after open heart surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9272529" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Safety of high energy internal cardioversion for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9358485" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Internal atrial defibrillation: effect on sinus and atrioventricular nodal function and implanted cardiac pacemakers.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
